Pharming Group N.V.
PHARM.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €287 | €245 | €206 | €190 |
| % Growth | 16.9% | 19.3% | 8.3% | – |
| Cost of Goods Sold | €43 | €25 | €18 | €20 |
| Gross Profit | €232 | €220 | €188 | €170 |
| % Margin | 80.8% | 89.7% | 91.5% | 89.4% |
| R&D Expenses | €73 | €69 | €53 | €67 |
| G&A Expenses | €92 | €81 | €46 | €35 |
| SG&A Expenses | €162 | €88 | €132 | €92 |
| Sales & Mktg Exp. | €7 | €7 | €86 | €57 |
| Other Operating Expenses | €0 | €69 | -€15 | -€3 |
| Operating Expenses | €235 | €225 | €170 | €157 |
| Operating Income | -€3 | -€5 | €18 | €28 |
| % Margin | -1.2% | -2% | 8.9% | 14.7% |
| Other Income/Exp. Net | -€4 | -€7 | -€3 | -€5 |
| Pre-Tax Income | -€8 | -€12 | €15 | €22 |
| Tax Expense | €2 | -€1 | €1 | €7 |
| Net Income | -€11 | -€11 | €14 | €16 |
| % Margin | -3.7% | -4.3% | 6.7% | 8.4% |
| EPS | -0.015 | -0.013 | 0.017 | 0.02 |
| % Growth | -20.3% | -176.2% | -16% | – |
| EPS Diluted | -0.015 | -0.013 | 0.015 | 0.018 |
| Weighted Avg Shares Out | 689 | 821 | 884 | 876 |
| Weighted Avg Shares Out Dil | 689 | 843 | 884 | 876 |
| Supplemental Information | – | – | – | – |
| Interest Income | €6 | €4 | €0 | €14 |
| Interest Expense | €9 | €6 | €5 | €6 |
| Depreciation & Amortization | €10 | €16 | €13 | €20 |
| EBITDA | €13 | €10 | €34 | €49 |
| % Margin | 4.6% | 4% | 16.3% | 25.7% |